Our Heritage is In Hematology
American Society of Hematology Annual Meeting 2020
Welcome Video from Our CEO, Jackie Fouse

ASH 2020 Data Room
View our latest news and presentations from the ASH Annual Meeting
NEWS
December 7, 2020
Agios Announces Updated Data from Phase 1 Study of Mitapivat, First-in-Class PKR Activator, in Sickle Cell Disease
Learn MoreNovember 4, 2020
Agios to Present Broad Set of Clinical and Translational Data for Oncology and Rare Genetic Disease Programs at the Virtual 2020 ASH Annual Meeting
Learn More
VIRTUAL EVENT: MITAPIVAT CLINICAL DATA
December 8, 2020 | 8:00 AM ET
Agios is hosting a virtual investor event to review the mitapivat clinical data. The event will be webcast live, and a replay will be available approximately two hours after the event.
ABSTRACTS
Access All ASH Abstracts
PRESENTATIONS & POSTERS
ORAL PRESENTATION
Abstract #625: Ivosidenib Improves Overall Survival Relative to Standard Therapies in Relapsed or Refractory Mutant IDH1 AML: Results from Matched Comparisons to Historical Controls
Date & Time: Monday, December 7, 2020 at 10:15 a.m. PST
Oral Session: 903. Health Services Research – Malignant Conditions (Myeloid Disease): Treatment and Publication Patterns in Myeloid Malignancies
Presenter: Peter Paschka, Klinikum Ludwigshafen
Read More >
POSTER PRESENTATIONS – RARE GENETIC DISEASES
Abstract #1627: Mortality Among Veterans with a Diagnosis of Pyruvate Kinase (PK) Deficiency: A Real-World Study Using US Veterans Health Administration Data
Poster Session Date & Time: Saturday, December 5, 2020 from 7:00 a.m. – 3:30 p.m. PST
Poster Session: 904. Outcomes Research – Non-Malignant Conditions: Poster I
Read More >
Abstract #1679: Early-Onset Osteopenia and Osteoporosis in Patients with Pyruvate Kinase Deficiency
Poster Session Date & Time: Sunday, December 6, 2020 from 7:00 a.m. – 3:30 p.m. PST
Poster Session: 101. Red Cells and Erythropoiesis, Structure and Function, Metabolism, and Survival, Excluding Iron: Poster II
Read More >
Abstract #2583: Baseline Characteristics of Patients in Peak: A Global, Longitudinal Registry of Patients with Pyruvate Kinase Deficiency
Poster Session Date & Time: Monday, December 7, 2020 from 7:00 a.m. – 3:30 p.m. PST
Poster Session: 101. Red Cells and Erythropoiesis, Structure and Function, Metabolism, and Survival, Excluding Iron: Poster III
Read More >
Abstract #2600: Proof of Concept for the Oral Pyruvate Kinase Activator Mitapivat in Adults with Non-Transfusion-Dependent Thalassemia: Interim Results from and Ongoing, Phase 2, Open-Label, Multicenter Study
Poster Session Date & Time: Monday, December 7, 2020 from 7:00 a.m. – 3:30 p.m. PST
Poster Session: 112. Thalassemia and Globin Gene Regulation: Poster III
Read More >
POSTER PRESENTATIONS – ONCOLOGY
Abstract #1943: Molecular Characterization of Clinical Response and Relapse in Patients with IDH1-Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosidenib and Azacitidine
Poster Session Date & Time: Sunday, December 6, 2020 from 7:00 a.m. – 3:30 p.m. PST
Poster Session: 615. Acute Myeloid Leukemia: Commercially Available Therapy, excluding Transplantation: Poster II
Read More >
Abstract #2814: AGILE: Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Ivosidenib in Combination with Azacitidine in Adults with Newly Diagnosed Acute Myeloid Leukemia and an IDH Mutation
Poster Session Date & Time: Monday, December 7, 2020 from 7:00 a.m. – 3:30 p.m. PST
Poster Session: 613. Acute Myeloid Leukemia: Clinical Studies: Poster III
Read More >
Abstract #2900: Longitudinal Molecular Profiling in Patients with IDH1-Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosidenib
Poster Session Date & Time: Monday, December 7, 2020 from 7:00 a.m. – 3:30 p.m. PST
Poster Session: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis Prognosis: Poster III
Read More >
PRESENTATIONS BY EXTERNAL COLLABORATORS
Oral Presentations
Abstract #84: The Pyruvate Kinase Activator AG-348 ameliorates anemia and prevents iron overload in a mouse model of hereditary spherocytosis
Date & Time: Saturday, December 5, 2020 at 10:15 a.m. PST
Oral Session: 101. Red Cells and Erythropoiesis, Structure, and Functions, Metabolism, and Survival, Excluding Iron: Mechanisms, Diagnosis and Treatment of Inherited
Presenter: Alessandro Mattè, BSc, PhD University of Verona and AOUI Verona
Read More >
Abstract #681: Phase 1 Multiple Ascending Dose Study of Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Mitapivat (AG-348) in Subjects with Sickle Cell Disease
Date & Time: Monday, December 7, 2020 at 2:30 p.m. PST
Oral Session: 114. Hemoglobinopathies Excluding Thalassemia – Clinical: Novel Treatments for Sickle Cell Disease
Presenter: Julia Z. Xu, Sickle Cell Branch, National Heart, Lung, and Blood Institute
Read More >
Poster Presentation
Abstract #2402: A Phase I Study of the IDH2 inhibitor enasidenib as maintenance therapy for IDH2-mutant myeloid neoplasms following hematopoietic
Date & Time: Sunday, December 6, 2020 from 7:00 a.m. – 3:30 p.m. PST
Poster Session: 723. Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence: Post II
Read More >
Follow along with Agios at #ASH20
Contact Us
Medical Information Inquiries
- Agios Medical Information Call Center
- Monday – Friday 7:00am – 6:00pm CT
- with Urgent After Hours
- medinfo@agios.com
- 833-228-8474
- 901-432-3977